Recent Insights into Farnesoid X Receptor in Non-alcoholic Fatty Liver Disease

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2014 Oct 14

PMID 25309079

Citations 17

Authors

Jiao-Ya Xu

Zhong-Ping Li

Li Zhang

Guang Ji

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is one of the most prevalent liver disorders worldwide. NAFLD can gradually progress to liver inflammation, fibrosis, cirrhosis and even hepatocellular carcinoma. However, the pathogenesis of NAFLD is complex, and no efficient pharmaceutic treatments have yet been established for NAFLD. Accumulating data have shown that the farnesoid X receptor (FXR) plays important roles not only in bile acid metabolism, but also in lipid and carbohydrate homeostasis, inflammatory responses, among others. In this review, we aim to highlight the role of FXR in the pathogenesis and treatment of NAFLD.

Citing Articles

From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension.

Porada M, Buldak L Metabolites. 2025; 15(2).

PMID: 39997697 PMC: 11857179. DOI: 10.3390/metabo15020072.

Farnesoid X receptor: From Structure to Function and Its Pharmacology in Liver Fibrosis.

Ding C, Wang Z, Dou X, Yang Q, Ning Y, Kao S Aging Dis. 2023; 15(4):1508-1536.

PMID: 37815898 PMC: 11272191. DOI: 10.14336/AD.2023.0830.

Hepatic Clstn3 Ameliorates Lipid Metabolism Disorders in High Fat Diet-Induced NAFLD through Activation of FXR.

Guo J, Huang S, Yi Q, Liu N, Cui T, Duan S ACS Omega. 2023; 8(29):26158-26169.

PMID: 37521618 PMC: 10373204. DOI: 10.1021/acsomega.3c02347.

Therapeutic targets in alcohol-associated liver disease: progress and challenges.

Adekunle A, Adejumo A, Singal A Therap Adv Gastroenterol. 2023; 16:17562848231170946.

PMID: 37187673 PMC: 10176580. DOI: 10.1177/17562848231170946.

EDP-297: A novel, farnesoid X receptor agonist-Results of a phase I study in healthy subjects.

Marotta C, Ahmad A, Luo E, Oosterhaven J, van Marle S, Adda N Clin Transl Sci. 2022; 16(2):338-351.

PMID: 36369848 PMC: 9926082. DOI: 10.1111/cts.13453.

References

Wu W, Zhu B, Peng X, Zhou M, Jia D, Gu J . Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem Biophys Res Commun. 2013; 443(1):68-73. DOI: 10.1016/j.bbrc.2013.11.057. View

Torra I, Claudel T, Duval C, Kosykh V, Fruchart J, Staels B . Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol. 2003; 17(2):259-72. DOI: 10.1210/me.2002-0120. View

Wang Y, Chen W, Moore D, Huang W . FXR: a metabolic regulator and cell protector. Cell Res. 2008; 18(11):1087-95. DOI: 10.1038/cr.2008.289. View

Musso G, Gambino R, Cassader M . Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res. 2012; 52(1):175-91. DOI: 10.1016/j.plipres.2012.11.002. View

Nomura K, Yamanouchi T . The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem. 2011; 23(3):203-8. DOI: 10.1016/j.jnutbio.2011.09.006. View

Li T, Matozel M, Boehme S, Kong B, Nilsson L, Guo G . Overexpression of cholesterol 7α-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis. Hepatology. 2011; 53(3):996-1006. PMC: 3079544. DOI: 10.1002/hep.24107. View

Yang Z, Shen W, Sun H . Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol Int. 2011; 4(4):741-8. PMC: 2994619. DOI: 10.1007/s12072-010-9202-6. View

Chiang J . Bile acid metabolism and signaling. Compr Physiol. 2013; 3(3):1191-212. PMC: 4422175. DOI: 10.1002/cphy.c120023. View

McMahan R, Wang X, Cheng L, Krisko T, Smith M, El Kasmi K . Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem. 2013; 288(17):11761-70. PMC: 3636865. DOI: 10.1074/jbc.M112.446575. View

10.

Mantena S, King A, Andringa K, Eccleston H, Bailey S . Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med. 2008; 44(7):1259-72. PMC: 2323912. DOI: 10.1016/j.freeradbiomed.2007.12.029. View

11.

Bhatia L, Curzen N, Calder P, Byrne C . Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur Heart J. 2012; 33(10):1190-200. DOI: 10.1093/eurheartj/ehr453. View

12.

Laffitte B, Kast H, Nguyen C, Zavacki A, Moore D, Edwards P . Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem. 2000; 275(14):10638-47. DOI: 10.1074/jbc.275.14.10638. View

13.

Lu Y, Ma Z, Zhang Z, Xiong X, Wang X, Zhang H . Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice. Gut. 2013; 63(1):170-8. DOI: 10.1136/gutjnl-2012-303150. View

14.

Enjoji M, Yasutake K, Kohjima M, Nakamuta M . Nutrition and nonalcoholic Fatty liver disease: the significance of cholesterol. Int J Hepatol. 2012; 2012:925807. PMC: 3328950. DOI: 10.1155/2012/925807. View

15.

Williamson R, Price J, Glancy S, Perry E, Nee L, Hayes P . Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011; 34(5):1139-44. PMC: 3114489. DOI: 10.2337/dc10-2229. View

16.

Zhang L, Wang Y, Chen W, Wang X, Lou G, Liu N . Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice. Hepatology. 2012; 56(6):2336-43. PMC: 3477501. DOI: 10.1002/hep.25905. View

17.

Inagaki T, Moschetta A, Lee Y, Peng L, Zhao G, Downes M . Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006; 103(10):3920-5. PMC: 1450165. DOI: 10.1073/pnas.0509592103. View

18.

Watanabe M, Horai Y, Houten S, Morimoto K, Sugizaki T, Arita E . Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J Biol Chem. 2011; 286(30):26913-20. PMC: 3143650. DOI: 10.1074/jbc.M111.248203. View

19.

Claudel T, Sturm E, Duez H, Torra I, Sirvent A, Kosykh V . Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest. 2002; 109(7):961-71. PMC: 150929. DOI: 10.1172/JCI14505. View

20.

Seo J, Kim N . Fibroblast growth factor 21: a novel metabolic regulator. Diabetes Metab J. 2012; 36(1):26-8. PMC: 3283823. DOI: 10.4093/dmj.2012.36.1.26. View